Recent developments in the field include an evolving treatment landscape and the development of evidence-based guidelines.

AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...